PMID- 28901416 OWN - NLM STAT- MEDLINE DCOM- 20180604 LR - 20180604 IS - 1791-3004 (Electronic) IS - 1791-2997 (Linking) VI - 16 IP - 5 DP - 2017 Nov TI - Protective role of berberine and Coptischinensis extract on T2MD rats and associated islet Rin‑5f cells. PG - 6981-6991 LID - 10.3892/mmr.2017.7467 [doi] AB - The aim of the present study was to compare the different effects of berberine (Ber) and Coptischinensis extract (CCE) on a rat model of type 2 diabetes mellitus (T2DM), and the islet Rin‑5f cell line was used to examine the differences between Ber and CCE and the underlying mechanisms. CCE was extracted and purified prior to analysis. Male Sprague‑Dawley rats were provided with a high‑fat diet to induce insulin resistance prior to injecting with streptozotocinto establish the T2DM model, the T2DM rats were treated with Ber and CCE, and blood samples and pancreatic tissues were obtained and compared to examine T2DM metabolic syndromes among the groups of rats, which included healthy rats, model rats, and model rats treated with Ber and CCE at different doses between 0 and 8 weeks. The protective effects of Ber and CCE on the Rin‑5f islet cell line were also evaluated. The effects on Rin‑5f cell proliferation and cell cycle, glucose‑stimulated insulin release test (GSIS), the anti‑apoptotic effects caused by fat induction, and protein expression levels of poly ADP‑ribose polymerase (PARP‑1) were evaluated. The results showed that the content of the prepared CCE was 96.07% for five alkaloids. When it was used for treatment of the T2DM rats, compared with Ber, metformin and rosiglitazone, the fasting blood glucose, glucosylated serum protein (GSP) and glucose infusion rate indicesin the fasting rats were ameliorated, compared with those in the T2MD rats, with no significant differences between treatment with Ber or CCE and metformin or rosiglitazone. The indices of mean optical density and fasting beta‑cell function index (FBCI) were different following treatment with Ber and CCE, compared with those in the model rats, which may have stimulated the pancreatic secretion of insulin. When Ber and CCE were used to examine the protective effects on Rin‑5F cells, it was found that the Rin‑5f cell GSIS, cell cycle, lipotoxic islet cell proliferation and protein expression of PARP‑1 were altered and improved, which may have protected pancreatic islet beta‑cells by improving islet beta‑cell proliferation and the protein expression of PARP‑1. CCE and Ber exerted similar effects when used for the treatment of T2MD rats, and may have stimulated the pancreatic secretion of insulin through the protective effect on islet beta‑cells via improving islet beta‑cell proliferation and the protein expression of PARP‑1. FAU - Jiang, Yu-Yu AU - Jiang YY AD - The Management of Chronic Disease and Rehabilitation Department, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China. FAU - Cui, Han-Ming AU - Cui HM AD - Department of Chinese Traditional Medicine Research and Development Center, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China. FAU - Wang, Jia-Long AU - Wang JL AD - Department of Chinese Traditional Medicine Research and Development Center, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China. FAU - Liu, Hui AU - Liu H AD - Department of Traditional Chinese Medicine, College of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China. FAU - Dang, Meng-Meng AU - Dang MM AD - Department of Traditional Chinese Medicine, College of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China. FAU - Zhang, Qiu-Yan AU - Zhang QY AD - Department of Chinese Traditional Medicine Research and Development Center, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China. FAU - Yang, Fang AU - Yang F AD - Department of Agriculture and Life Sciences, Ankang University, Ankang, Shaanxi 725000, P.R. China. FAU - Kou, Jian-Tao AU - Kou JT AD - Department of Orthopedics, Hebei Wen'an Hospital, Langfang, Hebei 065800, P.R. China. FAU - Tong, Xiao-Lin AU - Tong XL AD - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China. LA - eng PT - Journal Article DEP - 20170912 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Blood Glucose) RN - 0 (Glycation End Products, Advanced) RN - 0 (Insulin) RN - 0 (Plant Extracts) RN - 0 (Protective Agents) RN - 0I8Y3P32UF (Berberine) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Animals MH - Berberine/*pharmacology MH - Blood Glucose/analysis MH - Cell Cycle Checkpoints/drug effects MH - Cell Line MH - Cell Proliferation/*drug effects MH - Cell Survival/drug effects MH - Diabetes Mellitus, Type 2/metabolism/*pathology/veterinary MH - Diet, High-Fat MH - Glucose/metabolism MH - Glycation End Products, Advanced/analysis MH - Insulin/metabolism MH - Islets of Langerhans/cytology/metabolism MH - Male MH - Pancreas/metabolism/pathology MH - Plant Extracts/chemistry/*pharmacology MH - Protective Agents/*pharmacology MH - Ranunculaceae/chemistry/metabolism MH - Rats MH - Rats, Sprague-Dawley EDAT- 2017/09/14 06:00 MHDA- 2018/06/05 06:00 CRDT- 2017/09/14 06:00 PHST- 2016/06/22 00:00 [received] PHST- 2017/05/24 00:00 [accepted] PHST- 2017/09/14 06:00 [pubmed] PHST- 2018/06/05 06:00 [medline] PHST- 2017/09/14 06:00 [entrez] AID - 10.3892/mmr.2017.7467 [doi] PST - ppublish SO - Mol Med Rep. 2017 Nov;16(5):6981-6991. doi: 10.3892/mmr.2017.7467. Epub 2017 Sep 12.